The gut is not a monolith.
A single dietary intervention can shield one section of the intestine while handing a loaded gun to another. This isn’t science fiction. It’s the jarring reality emerging from new MIT research published in Nature.
Ketogenic diets—the high-fat, ultra-low-carb regimens popular for weight loss and now touted for anti-aging and cancer suppression—are acting like a double agent in the gastrointestinal tract.
They suppress colon tumors.
They accelerate small intestine cancer.
The findings dismantle the simple “keto good, keto bad” narrative. They suggest that what saves the colon may actively fuel disease in the small intestine. And for people with genetic risks, the distinction isn’t just academic. It’s survival.
The Metabolic Switch Behind the Trend
To understand the risk, you have to understand the fuel.
Ketogenic diets originated in the 1920s for epilepsy. Children who wouldn’t respond to meds got better on fat-heavy meals. Decades later, the diet pivoted to weight loss, then to metabolic health. The mechanism is consistent: starve the body of glucose, force it to burn fat, and produce ketone bodies.
The primary ketones are β-hydroxybutyrate (often called BHB) and acetoacetate.
For years, these molecules were dismissed as metabolic exhaust. Now, they’re seen as signaling powerhouses. They influence inflammation, gene expression, and cellular energy use. The hypothesis was seductive: if BHB suppresses tumors in the colon, the diet must be broadly protective against cancer.
That hypothesis collapsed in the small intestine.
The Small Intestine Paradox
In 2022, a Nature study showed BHB reducing colon tumor formation. The MIT team wondered: does the diet offer similar protection lower down?
They looked at mice genetically predisposed to intestinal cancer.
The results were stark.
Mice on a ketogenic diet developed small intestinal tumors more frequently. Not significantly more due to weight gain—they didn’t become obese. In fact, they remained lean. Yet their tumor rates matched, or exceeded, mice fed an obesogenic high-calorie, high-fat diet.
The diet didn’t cause cancer because the mice were fat.
It caused cancer because their bodies were drowning in dietary lipids.
Fat, Not Ketones, Fuels the Fire
This is where the conventional wisdom breaks down.
The study authors fully expected BHB to be the driver. Commercial ketone drinks promise benefits based on high blood levels of these compounds. But the data told a different story.
BHB played no significant role in driving tumor growth in the small intestine.
Instead, it was the fatty acids themselves.
Cells in the small intestine lining burned through the excess dietary fat via fatty acid oxidation. This process activated proteins called PPARs (peroxisome proliferator-activated receptors). These proteins regulate how cells process fat.
When PPARs switched on, they sent a signal to intestinal stem cells to divide faster.
Stem cells are essential. The intestinal lining is one of the most rapidly renewing tissues in the human body. Without these stem cells, we couldn’t repair damage or replace worn-out cells.
But rapid division is a double-edged sword.
More divisions mean more chances for errors. More errors mean higher risk of mutations.
“Having more stem cells means that, when you injure the small intestine, the repair is better, but the downside is having more active stem cells that can lead to tumor formation,” explained Omer Yilmaz, the study’s senior author and director of the MIT Stem Cell Initiative.
The colon responded differently. The ketogenic diet still reduced tumor formation there. But even in the colon, BHB wasn’t the direct agent of protection. The molecules were essentially “metabolic bystanders.”
The real story was how stem cells processed the heavy influx of dietary fat in the small intestine.
Why The Gut Reacts So Differently
The colon and the small intestine are neighbors. They share the same bloodstream. They face the same diet.
So why do they react like opposites?
“We’re working to understand why the same diet has opposite consequences in these two adjacent parts of the gut,” said lead author Fangtao Chi.
The mechanism likely involves differences in how these tissues metabolize lipids. The small intestine is designed to absorb nutrients, including fats, into the bloodstream. It has a high baseline rate of nutrient processing. The colon is different; it handles water absorption and waste formation.
The specific interaction between PPAR activation and stem cell turnover in the small intestine appears to be the tipping point.
The Implication For Supplements And Risk
Here is a critical detail often missed in health journalism.
The tumor growth in the study was driven by dietary fat. Specifically, the way intestinal cells processed a high volume of fat from food.
This suggests a major flaw in the commercial ketone supplement market.
Taking ketone drinks or pills raises blood levels of BHB without adding a surge of dietary fatty acids for the gut cells to burn. According to these findings, supplements would not reproduce the increased small intestinal tumor risk. They also might not trigger the protective colon effects observed in the diet-fed mice.
The compounds in your blood are not the same as the lipids passing through your gut lining.
This distinction matters most for those with inherited cancer risks.
Familial adenomatous polyposis (FAP) and other genetic conditions already raise the stakes for intestinal tumors. Cases of small intestine cancer have risen in recent decades, even as colon cancer rates have begun to plateau.
For these individuals, a “one size fits all” keto approach could be dangerous.
The Generalization Trap
The broader scientific lesson here is about humility.
Diets cannot be classified simply as beneficial or harmful. Their effects vary dramatically across tissues.
A diet that slows cancer in one part of the body may accelerate it inches away. The gut is not a uniform organ. It is a mosaic of distinct biological environments, each responding to metabolic shifts in its own unique way.
“Ketogenic diets have distinct effects… what might be beneficial for one tissue may actually be detrimental for another,” Yilmaz noted.
The media loves a simple headline. “Keto Fights Cancer.” “Keto Causes Cancer.”
Both are wrong.
The truth is messier. It involves stem cells, PPAR signaling, and the complex reality that biology rarely bends to the elegance of a dietary trend.
Until researchers understand why the colon and small intestine react so differently to the same lipids, the advice should remain cautious.
Especially for those whose genetics have already painted a target on their intestines.
Reference:
“Ketogenic diet mediates intestinal tumorigesis through lipids not ketones,” by Jessica E. S. Shay et al., Nature, 15 July 2024. DOI: 10.1038/41586-017-6583-7
